Aeris Biotechnologies
Early Stage
A Groundbreaking Approach to Asthma & Allergy
Overview
Raised: $95,200
Total Commitments ($USD)
Platform
Dalmore Group
Start Date
07/26/2022
Close Date
07/26/2023
Min. Goal
$500
Max. Goal
$15,000,000
Min. Investment
$500
Security Type
Equity - Common
Series
Pre-Seed
SEC Filing Type
RegA+
Price Per Share
$1.00
Pre-Money Valuation
$28,350,000
Rolling Commitments ($USD)
Status
Active
Reporting Date
06/07/2023
Days Remaining
49
% of Min. Goal
19,040%
% of Max. Goal
1%
Likelihood of Max
Avg. Daily Raise
$301
# of Investors
8
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2021
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2C
Margin
Medium
Capital Intensity
High
Aeris Biotechnologies is raising funds through Reg A+ crowdfunding with Dalmore Group as the Broker-Dealer. The company is bringing an innovative and green approach to the treatment of asthma. The business has developed a first-of-its-kind, in-home, and affordable treatment kit to control the dust mites and associated allergens that cause asthma. The technology of Aeris Biotechnologies is green, scalable, and patent-protected. Aaron Michael Gunn and Dr. David Richard Harper founded Aeris Biotechnologies in 2021. The current crowdfunding campaign has a maximum target of $15,000,000. The campaign proceeds will be used for business development, marketing, research and development, product development, and working capital.
Balance Sheet
|
Cash and Cash Equivalents |
$33,242 |
| Total Assets |
$33,242 |
|
Accounts Payable & Accrued Liabilities |
$104,548 |
|
Long Term Debt |
$50,000 |
|
Total Liabilities |
$104,548 |
|
Total Stockholders' Equity |
$-71,306 |
| Total Liabilities and Equity |
$33,242 |
Statement of Comprehensive Income Information
| Net Income |
$0 |
|
Earnings Per Share - Basic |
$0.00 |
|
Earnings Per Share - Diluted |
$0.00 |
Auditor: BF Borgers CPA PC
Financials as of: 07/26/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.